Clinical Effect and Safety Analysis of Rebamipide Modified Quadruple Chemotherapy in the Treatment of Helicobacter Pylori Positive Gastric Ul-cer
Objective To explore the clinical efficacy and safety of rebamipide modified quadruple chemotherapy in the treatment of helicobacter pylori(Hp)positive gastric ulcer.Methods A total of 146 patients with Hp-positive gas-tric ulcer admitted to Shanxian Central Hospital from January 2023 to April 2024 were selected as the research ob-jects.According to different treatment methods,they were divided into conventional group and exploration group.The conventional group(73 cases)received bismuth-containing quadruple chematherapy,and the exploration group(73 cases)was treated with rebamipide modified quadruple chemotherapy.The levels of inflammatory factors,gastric mu-cosal morphology,gastric function,the total incidence of adverse reactions and Hp eradication rate were compared be-tween the two groups.Results After treatment,the level of inflammatory factors in the exploration group was lower than that in the conventional group,and the difference was statistically significant(P<0.05).The morphological level of gastric mucosa and gastric function in the exploration group were better than those in the conventional group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in the exploration group was 6.85%(5/73),which was lower than 17.81%(13/73)in the conventional group,and the eradication rate of Hp in the exploration group was 94.52%(69/73),which was higher than 82.19%(60/73)in the conventional group,the differ-ences were statistically significant(χ2=4.056,5.393;both P<0.05).Conclusion In the treatment of Hp-positive gastric ulcer,compared with traditional bismuth-containing quadruple chemotherapy,rebamipide modified quadruple chema-therapy can improve inflammatory response,gastric function and severity of gastric mucosal lesions,with low inci-dence of adverse reactions and high eradication rate of Hp.
万方数据
维普
